Emergent BioSolutions Inc.
EBS
$8.50
-$0.45-5.03%
NYSE
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 4.98% | -35.66% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 4.98% | -35.66% | |||
| Cost of Revenue | -12.34% | -5.05% | |||
| Gross Profit | 34.73% | -58.59% | |||
| SG&A Expenses | -24.35% | 117.67% | |||
| Depreciation & Amortization | 1.23% | 0.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -15.06% | 19.12% | |||
| Operating Income | 146.90% | -125.89% | |||
| Income Before Tax | 126.43% | -188.02% | |||
| Income Tax Expenses | 69.23% | -39.06% | |||
| Earnings from Continuing Operations | 112.45% | -206.64% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 112.45% | -206.64% | |||
| EBIT | 146.90% | -125.89% | |||
| EBITDA | 33,600.00% | -100.09% | |||
| EPS Basic | 112.57% | -208.27% | |||
| Normalized Basic EPS | 130.03% | -167.38% | |||
| EPS Diluted | 107.13% | -214.51% | |||
| Normalized Diluted EPS | 127.57% | -171.57% | |||
| Average Basic Shares Outstanding | -0.95% | -1.50% | |||
| Average Diluted Shares Outstanding | 7.82% | -7.26% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||